Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
90 Cards in this Set
- Front
- Back
differential diagnosis for increased blood glucose (DM)
|
pancreatic disease (chronic pancreatitis), glucagonoma, Cushing's disease, iatrogenic (corticosteroids), gestational DM, diabetes insipidus
|
|
Describe the honeymoon period in type 1 DM
|
a remission phase seen in type 1 DM days after initiation of insulin therapy, where they have decreased insulin requirements for several months
|
|
pathophysiology of type 1 DM
|
autoimmune destruction of beta cells
|
|
pathophysiology of type 2 DM
|
insulin resistance and inadequate insulin secretion by pancreas
|
|
in which type of DM are classic symptoms more common?
|
type 1 DM
|
|
differential diagnosis for increased blood glucose (DM)
|
pancreatic disease (chronic pancreatitis), glucagonoma, Cushing's disease, iatrogenic (corticosteroids), gestational DM, diabetes insipidus
|
|
genetic predisposition of type 1 DM
|
weak, polygenic in type 1, with association to HLA DR3 and DR4; strong polygenic in type 2 with no HLA association
|
|
Describe the honeymoon period in type 1 DM
|
a remission phase seen in type 1 DM days after initiation of insulin therapy, where they have decreased insulin requirements for several months
|
|
common regimen of type 1 DM
|
MDI regimen (premeal HR and bedtime glargine)
|
|
pathophysiology of type 1 DM
|
autoimmune destruction of beta cells
|
|
short-acting insulin
|
Lispro or Aspart
|
|
pathophysiology of type 2 DM
|
insulin resistance and inadequate insulin secretion by pancreas
|
|
frequency of HbA1c checkups
|
every 3 months
|
|
in which type of DM are classic symptoms more common?
|
type 1 DM
|
|
HbA1C goal
|
<7
|
|
genetic predisposition of type 1 DM
|
weak, polygenic in type 1, with association to HLA DR3 and DR4; strong polygenic in type 2 with no HLA association
|
|
common regimen of type 1 DM
|
MDI regimen (premeal HR and bedtime glargine)
|
|
short-acting insulin
|
Lispro or Aspart
|
|
frequency of HbA1c checkups
|
every 3 months
|
|
HbA1C goal
|
<7
|
|
when to obtain baseline ECG in type 1 DM patients?
|
if with heart disease or is <35 y/o
|
|
typical stepwise pharmacologic management of type 2 DM
|
metformin, a glitazone, and a sulfonylurea (glyburide); if inadequate on 3 drugs, replace glyburide with NPH or glargine insulin at bedtime; if more intense therapy needed, split/mixed regimen of HR and NPH
|
|
symptoms and diagnostic findigns in DKA
|
fruity breath odor, Kussmaul hyperpnea, DHN, abdominal pain, increased AG, hyperkalemia, hyperglycemia, ketones in blood and urine
|
|
criteria for HHNK
|
glu >600; pH <7.3; bicarb >15, AG < 14, osmolality >310
|
|
types of DM retinopathy
|
nonproliferative and proliferative
|
|
describe nonproliferative DM retinopathy
|
retinal vascular microaneurysms, blot hemorrhages, cotton wool spots, macular edema
|
|
describe proliferative retinopathy
|
neovascularization in response to retinal hypoxia
|
|
diagnostic findings in kidney biopsy in DM
|
Kimmelstiel-Wilson lesions (nodular glomerulosclerosis)
|
|
treatment of nephropathy
|
patients with microalbuminuria or proteinuria should be started on ACEi to achieve BP of <125/75
|
|
treatment of neurpopathy
|
stict glycemic control improves nerve conduction; TCAs and carbamazepine for sensory dysfunction
|
|
describe myxedema coma
|
a form of severe hypothyroidism characterized by AMS and hypothermia
|
|
describe thyroid storm
|
a form of severe hyperthyroidism characterized by high fever, DHN, tachycardia, coma and high-output cardiac failure
|
|
diagnostic tests for patients with decreased TSH
|
order RAIU scan, TG antibody and thyroid-stimulating Ig assays
|
|
diagnostic tests for patients with increased TSH
|
order anti-thyroid peroxidase antibody assay
|
|
symptomatic treatment of hyperthyroidism
|
propranolol, hydration, rest, adequate nutrition, cooling measures if severe hyperthermia
|
|
pharmacologic treatment of hyperthyroidism
|
PTU or methimazole; severe cases require RAI thyroid ablation; thyroidectomy
|
|
indications for thyroidectomy
|
large goiters, pregnanat patients, obstruction of trachea
|
|
pharmacologic treatment of hypothyroidism
|
levothyroxine; IV levothyroxine and IV hydrocortisone for myxedema coma patients
|
|
most common cause of primary hyperparathyroidism
|
parathyroid adenoma
|
|
common fractures seen in osteoporotic patients
|
hip fractures, vertebral compression fractures, distal radius fractures following minimal trauma
|
|
who should be screened for osteoporosis?
|
all patients >65 y/o; patients 40-60 y/o with at least 1 RF for osteoporotic fractures after menopause
|
|
screening test for osteoporosis
|
DEXA scan of spine and hip
|
|
interpretation of Dexa scan
|
take the lowest T-score between spine and hip; if -1 to -2.5 diagnosis is osteopenia; if </= 2.5 diagnosis is osteoporosis
|
|
secondary causes of osteoporosis
|
smoking, alcoholism, renal failure, hyperthyroidism, MM, primary hyperparathyroidism, vitamin D deficiency, hypercortisolism, heparin use, chronic steroid use
|
|
when to start treatment in osteoporosis
|
if T-score is <-2; of <-1.5 with RF for fractures
|
|
DOC for osteoporosis, in order of efficacy
|
bisphosphonates, teriparatide, SERMs, intranasal calcitonin
|
|
bisphosphonates
|
alendronate, etidronate, ibandronate
|
|
SERMs
|
selective estrogen receptor modulators (raloxifene)
|
|
how often should DEXA scans be repeated
|
every 1-2 years after initiation of drug therapy; if worsened T-scores, start combination therapy or change drug
|
|
what is Cushing's disease
|
Cushing's syndrome caused by hypersecretion of ACTH from pituitary adenoma
|
|
etiologies of hypercortisolism
|
adrenal (adenoma, carcinoma),"", pituitary adenoma, ectopic (lung CA), exogenous (CS administration)
|
|
symptoms of Cushing's disease
|
truncal obesity, moon facies, buffalo hump; psych disturbances, HTN, impotence, oligomenorrhea, growth retardation, hirsutism, easy bruisability, purple stria
|
|
diagnostic for Cushing's syndrome
|
increased 24-hour urine cortisol
|
|
algorithm for Cushing's syndrome (increased 24 h urine cortisol)
|
check AM serum ACTH; if <5, give exogenous steroids or obtain adrenal CT or MRI; if >5, give high-dose dexa suppression test
|
|
interpretation of high-dose dexamathasone suppression test
|
suppressed = cushing's disease (confirm with pituitary MRI); nonsuppressed = ectopic ACTH producing tumor (carcinoid tumors, small cell lung CA)
|
|
What is Addison's diseas
|
primary adrenal insufficiency
|
|
when is DHEA most elevated
|
adrenal carcinoma
|
|
etiologies of primary adrenal insufficiency
|
autoimmune, metastatic tumor, hemorrhagic infarction, adrenalectomy, granulomatous disease (TB, sarcoid)
|
|
etiologies of secondary adrenal insufficiency
|
withdrawal of steroids, hypothalamic or pituitary pathology (tumor, infarct, trauma, infection, iatrogenic)
|
|
symptoms of adrenal insuff
|
weakness, anorexia, weight loss, N/V, postural hypotension, diarrhea, abdominal pain, myalgias, arthralgias
|
|
symptoms of addisonian crisis
|
symptomatic adrenal insufficiency, confusion, vasodilatory shock
|
|
diagnostic of adrenal insuff
|
AM serum cortisol <5 or <20 after ACTH stimulation test or <9 increase after same test
|
|
nonspecific lab findings for adrenal insufficiency
|
hyponatremia, hyperkalemia, eosinophilia
|
|
how to differnetiate primary from secondary adrenal insufficiency based on diagnostic tests
|
ACTH increased in primary and decreased in secondary; cortisol after ACTH challenge decreases in primary and increases in secondary
|
|
treatment of adrenal insufficiency
|
glucocorticoids and mineralocorticoids
|
|
DOC for adrenal insufficiency
|
hydrocortisone
|
|
treatment of OH/hyponatremia, hyperkalemia in adrenal insufficiency
|
fludrocortisone
|
|
most common functional pituitary tumor
|
prolactinoma
|
|
lab findings in prolactinoma
|
increased prolactin, decreased LH and FSH; MRI to confirm tumor
|
|
traetment of prolactinoma
|
dopamin agonist (bromocriptine or cabergoline); transsphenoidal surgery ffd by irradiation if tumor is large or medical therapy not tolerated
|
|
MEN type 1
|
Wermer's syndrome; pituitary adenoma; parathyroid hyperplasia; pancreatic islet cell tumor
|
|
MEN Type 2a
|
Sipple's syndrome; parathyroid hyperplasia; thryoid medullary cancer, pheochromocytoma
|
|
MEN Type 2b
|
thyroid medullary cancer, pheochromocytoma, mucocutaneous neuromas, ganglioneuromatosis of colon, Marfan-like habitus
|
|
symptoms of hyperparathyroidism
|
fatigue, constipation, polyuria, polydipsia, bone pain, nausea
|
|
diagnostic findings in primary hyperparathyroidism
|
increased calcium and PTH, low PO4
|
|
diagnostic findings in hypercalcemia not due to primary hyperparathyroidism
|
increased calcium, low or normal PTH, sometimes increased PO4
|
|
treatment of primary hyperparathyroidism
|
surgical removal or parathyroid glands; hydrate, furosemide after deficit corrected, bisphophonates for severe hypercalcemia
|
|
complications of primary hyperparathyroidism
|
nephrolithiasis, nephrocalcinosis, osteopenia, osteoporosis, pancreatitis, cardiac valve calcifications
|
|
pathophysiology of Grave's disease
|
Ab to TSH receptor
|
|
pathophysiology of subacute thyroiditis
|
viral infection (mumps or coxsackievirus)
|
|
pathophysiology of Hashimoto's thyroiditis
|
autoimmune
|
|
diagnostic findings in Grave's disease
|
decreased RAIU scan, (+) Thyroid-stim Ig; (+) Thyroglobulin Ab
|
|
diagnostic findings in subacute thyroiditis
|
increased RAIU scan; (+) Thyroglobulin Ab, high ESR
|
|
diagnostic findings in Hashimoto's thyroiditis
|
(+) anti-TPO Ab
|
|
treatment of Grave's
|
PTU, methimazole, thyroid ablation
|
|
treatment of subacute thyroiditis
|
NSAIds, steroids for severe pain; self-limited
|
|
treatment of Hashimoto's thyroiditis
|
levothyroxine
|
|
painless thyroid enlargement
|
Hashimoto's thyroiditis
|
|
hyperthyroidism --> hypothyroidism; tender thyroid
|
subacute thyroiditis
|
|
diffuse painless goiter with eye signs, pretibial myxedema and hyperthyroidism
|
Grave's disease
|